The FDA has approved Ozempic for type 2 diabetes, but it’s also known for its use off-label for weightloss. The agency has authorized NovoNordisk’s Wegovy—which shares the same active ...
The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved a body weightloss of 9.7% ... for Development at NovoNordisk. "The results seen ...